AstraZeneca PLC (AZN) operating KPIs
AZNNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Score 12/30
$163.95−1.46 (-0.88%)
Close on Oct 19, 2026Market cap $255.76BP/E 25.1Yield 1.91%
AstraZeneca imjudo (tremelimumab) — US product sales ($M) ($M)
Form 6-K / 20-F Product Sales Table
Latest, Q2 2026
51
Period ended Jun 30, 2026
Change on a year earlier
-10.5%
57 in Q2 2025
History
10 quarters
Since Q1 2024
Sources
10
Documents cited below
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Imjudo (tremelimumab) — US product sales ($M) ($M) | Year on year | Source |
|---|---|---|---|---|
| Q2 2026 | Jun 30, 2026 | 51 | -10.5% | Form 6-K FY2026Q2 Earnings Release ↗ |
| Q1 2026 | Mar 31, 2026 | 49 | -7.5% | Form 6-K FY2026Q1 Earnings Release ↗ |
| Q4 2025 | Dec 31, 2025 | 62 | +37.8% | Form 6-K FY2025Q4 Earnings Release ↗ |
| Q3 2025 | Sep 30, 2025 | 55 | +19.6% | Form 6-K FY2025Q3 Earnings Release ↗ |
| Q2 2025 | Jun 30, 2025 | 57 | +16.3% | Form 6-K FY2025Q2 Earnings Release ↗ |
| Q1 2025 | Mar 31, 2025 | 53 | +35.9% | Form 6-K FY2025Q1 Earnings Release ↗ |
| Q4 2024 | Dec 31, 2024 | 45 | – | Form 6-K FY2024Q4 Earnings Release ↗ |
| Q3 2024 | Sep 30, 2024 | 46 | – | Form 6-K FY2024Q3 Earnings Release ↗ |
| Q2 2024 | Jun 30, 2024 | 49 | – | Form 6-K FY2024Q2 Earnings Release ↗ |
| Q1 2024 | Mar 31, 2024 | 39 | – | Form 6-K FY2024Q1 Earnings Release ↗ |
Breakdown
What makes up imjudo (tremelimumab) — us product sales ($m)
Cite this data
StockData. (2026). AstraZeneca Imjudo (tremelimumab) — US product sales ($M) ($M), quarterly Q1 2024–Q2 2026 [Data set]. Compiled from AstraZeneca SEC filings and investor materials. https://stockdatahq.com/stocks/azn/kpis/med_imjudo_us
See every metric in the AstraZeneca KPI table. Data updated Oct 28, 2026.